- Oral presentation
- Open Access
What has been the contribution of the first Global Fund grant (2003-2006) to malaria control and health system strengthening in Timor-Leste?
© Martins et al; licensee BioMed Central Ltd. 2010
- Published: 20 October 2010
- Focus Group Discussion
- Malaria Control
- Global Fund
The Global Fund to fight against AIDS, Tuberculosis and Malaria was established in Geneva in January 2002 with the main objective of mobilizing resources from governments, donors, private sector and individuals to tackle HIV/AIDS, tuberculosis and malaria worldwide. Timor-Leste successfully obtained the first Global Fund grant with a value of nearly US $3 million in 2003 for a three-year program for malaria control. The grant was aimed at reducing malaria-related morbidity and mortality by 30% by the end of the implementation. Necessary structures required by the Global Fund to allow grant implementation were established.
A mixed methods approach was used to assess the impact of the grant implementation. The qualitative method employed in-depth interviews, group interviews, focus group discussions and observations. The quantitative method used the routinely collected morbidity data reported to the Ministry of Health.
Despite limitations, the grant was maintained until the agreed closing date. Considerable contributions to malaria control, health system and community have been made.
- Global Fund: Program grant agreement between the Global Fund to fight AIDS, Tuberculosis and Malaria and the Ministry of Health of the Government of the Democratic Republic of Timor-Leste. Geneva: The Global Fund to fight AIDS, Tuberculosis and Malaria. 2003Google Scholar
- Global Fund: Annual Report 2002/2003. Geneva: The Global Fund to fight AIDS,Tuberculosisand Malaria. 2003Google Scholar
- Martins JS, Zwi AB, Martins N, Kelly PM: Malaria control in Timor-Leste during a period of political instability: what lessons can be learned?. Confl Health. 2009, 3: 11-10.1186/1752-1505-3-11.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.